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Clinical research aims to understand diagnostic methods, diseases, and new treatments or 
medical devices that can advance patient care. The COVID-19 pandemic in 2020, a respiratory 
disease caused by SARS-CoV-2, impacted clinical research units in healthcare and brought new 
perspectives on how to better the future of clinical research by adopting modern technology. 
Clinical research has encountered much advancement over the years, with technology being the 
primary factor that accelerates clinical research growth. Incorporating new technology in clinical 
research translates to increased productivity and efficacy in patient engagements, trial 
management, novel outcomes, and reduced patient burden. The application of new technology in 
clinical research and next-generation clinical trials can be made effectively with lower costs and 
more accurate data. In this paper, an in-depth literature review was done to evaluate and discuss 
how the COVID-19 pandemic brought new transformations to clinical research and how the 
incorporated technology will transform in the future to optimize patient care.  Many remote 
technologies were deployed, such as eConsent, home care visits, and direct drug delivery, resulting 
in better data collection and saving time and resources.  
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Clinical research is an integral aspect of healthcare because it promotes the development 
of new interventions aimed at addressing identified health issues. The National Institute of Health 
(NIH) defined clinical research as one that involves human subjects and utilizes materials from 
human subjects such as samples of their tissues or behavior. It is vital in the development of new 
pharmaceutical drugs. The drug development process entails pharmacological and 
pharmacodynamic studies of the product to observe any potential side effects it may have on 
patients1. The process includes studying human subjects' reactions to the product, the absorption, 
distribution, metabolism, excretion (ADME) of the investigational product, and its safety and 
efficacy. The knowledge derived from clinical research is utilized to produce products and design 
processes that help prevent, diagnose, prognose, treat, and potentially cure patients of a particular 
condition or disease. Clinical trials are typically pursued to discover the knowledge of new 
treatments and behavioral interventions. The treatments usually conducted in human trials often 
entail assessing new novel vaccines, nutritional choices, drugs, and medical devices. The practice 
of clinical research has evolved as diseases become more complex and increasingly infectious, 
which has necessitated improved developmental processes to ensure populations' safety.  
Due to the nature of clinical research, patients might be harmed, which necessitates 
rigorous measures to ensure their safety. Clinical research has evolved from traditional clinical 
methodologies to modern clinical research2. The trials are cautiously planned, revised, and 
finalized before being submitted to an ethics committee (i.e., Institutional Review Board, etc.) for 
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approval because they involve human subjects. Anyone is allowed to participate regardless of age. 
Other measures adopted include the four stages of clinical research trials. Stage 1 entails 
identifying a safe drug dose limit and its side effects in a few people. It is usually conducted on 20 
to 100 healthy research participants. Phase 2 studies test the drug's efficacy due to it being found 
to be safe in phase 1, and it involves more research participants (around 100 up to 300) and entails 
observing any harmful effects. Phase 3 evaluations are done to assess the therapeutic effect of the 
drug. It is conducted on larger populations, usually 300 to 3000 individuals in different regions 
and countries. Phase 4 studies are usually termed as post-marketing surveillance, and they take 
place after country approval to assess the long-term drug effects3. These rigorous processes ensure 
the safety of patients who eventually use the developed drugs. However, the complexity of 
diseases, especially infectious diseases, has mandated a change in the clinical research process 
because of researchers, clinicians, and patients' safety issues.    
Particulalry, the emergence of Covid-19 disease in 2020 resulted in a new perspective in 
the clinical research field. According to a study by Dorn (2020), it disrupted clinical trials 
worldwide with long-lasting effects on medical science. The virus has severely affected the ability 
to conduct clinical trial research in safe and effective ways. Most clinical trials often deal with 
vulnerable populations who are at risk of infections from COVID-19. Thousands of non-COVID-
19 trials have been halted because of government-imposed lockdowns to limit the spread of the 
virus. The virus has also resulted in considerable reorientation in the way that clinical research is 
conducted towards COVID-19. These aspects -the disruption of clinical trials and the need to 
adjust to the challenging environment- have reinforced the need for quick and optimized clinical 
trials and modern technology in clinical research practices to curb the pandemic and other diseases 
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that could develop into pandemic proportions in the future through continued safe and effective 
clinical research and trials.  
Today, thousands of COVID-19 vaccine studies are being conducted globally to develop 
an effective vaccine for COVID-19. The biggest problems in clinical research, which have also 
been revealed in the trials done during the COVID-19 clinical tests, are that they are expensive to 
perform, and time-consuming depending on the protocol's design. The Coronavirus is risky for 
both patients and scientists (the risk of infection is high). Clinical trials naturally take a long time 
to complete and require many participants' continuous monitoring. The government imposed 
lockdowns and patients isolation measures have created challenging environment for conducting 
clinical trials. Besides, many organizations rely on an archaic way of documenting information via 
paper. Although technology is proliferating in this era, it is not fully utilized in clinical trial settings 
because stakeholders have been slow to embrace new changes4. The inertia to integrate technology 
into clinical research trials is now being felt as the COVID-19 ravages the public and threatens 
entire nations' well-being. However, the race and need to develop an effective vaccine has never 
been more dire. The challenge is how technology could help address the clinical research process 
under such challenging conditions to manage the COVID-19 pandemic effectively.  
1.2. Statement of the Problem 
Although the purpose of clinical research and trials in improving the quality of patient care 
has been discussed thoroughly in the literature, technology's role has not been fully explored. The 
study by Aimee (2015) revealed that one of the key factors for the sluggish adoption of e-
technology in clinical research is the limited empirical evidence on whether these technologies 
enhance or improve the design of clinical trials. Moreover, there is limited information about the 
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type of technologies that could facilitate clinical research trials from onboarding participants, 
collecting data, and monitoring patients under study.  Clinical trials' goal is to assess new 
experiments and treatments and identify their side effects on patients5 . The process involves 
participants in different sites, all with different conditions. Another significant factor for the 
sluggish integration of technology into clinical research is the lengthy regulatory requirements that 
delay the planning and commencement of clinical research activities. Before a participant enrolls 
in a clinical trial, they must undergo an informed consent process where they are informed fully 
about the study's purpose, the risks involved, the benefits, the length of the study, and what happens 
during the study. With the COVID-19 pandemic, these processes have been largely hampered as 
lockdowns and isolation strategies (social distancing) take root to limit rates of infections. Clinical 
researchers continue to grapple with issues like difficulties in structuring and prioritizing research 
questions, how to observe the ethical considerations diligently, and the challenge of globalizing 
clinical trials (Rosa, Campbell, Miele, Brunner, & Winstanley, 2015). Incorporating modern 
technology and utilizing it to optimize clinical research is also a challenge in clinical. 
Understanding how technology could facilitate and fast-track clinical process is vital in helping 
stakeholders address the challenges faced during the COVID-19 pandemic. The information could 
also promote sustainable and quality clinical research in the future. 
1.3. Research Questions 
 In light of the Covid-19 pandemic, pre-existing clinical research technologies are being 
forcibly thrust into the working environment that many were not designed for. In enhancing future 
clinical research, how could new technologies function according to ethical regulations and 
perform quality clinical research while minimizing deviations caused by human error? 
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Research Objectives 
1. To understand the key concepts in clinical research, such as recruitment and protection  
of human subjects and how new technologies and software could improve the process. 
2. To evaluate the impact of COVID-19 on future clinical research. 
3.  To evaluate the impact of incorporating modern technology in the future of clinical 
research.  
4. To identify a focus for future clinical research. 
1.4. Background and Significance of Problem 
Clinical research participants often volunteer for clinical trials and bear the associated risks 
without any guarantee for direct benefits. The COVID-19 pandemic presents significant challenges 
in addition to these risks, including the safety of researchers. Clinical trials have been the premier 
method for testing and validating new drugs and therapies. The approval of such medicines is 
based on successful trials in their safety and efficacy. The growing pressures on the clinical 
research processes during the COVID-19 pandemic coupled with the risks involved call for the 
integration of technologies that will help minimize the challenges and fast track the development 
of new drugs and therapies. Safety, accurate data collection, and proper participant monitoring are 
critical to successful clinical trials during such times.  
The FDA has long warned against clinical research trials that put the participants at risk 
and poor compliance with approved research protocols. Drawing from insights from the past harms 
on research participants necessitates that the findings of this study be seriously considered to 
protect both participants and scientists given the high infection rate of the Coronavirus. 
Technology could help address FDA warnings such as the failure to maintain adequate and 
accurate case histories that record all observations and other data integral to investigations on the 
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efficacy of the tested drugs (Browning, 2019). The digital records generated or captured and stored 
in digital databases duing clinical research could be audited to identify issues such as the 
researchers' failure to protect the rights, safety, and welfare of the clinical trial participants, report 
adverse reactions to the developed drugs, or fail to provide timely treatment to participants who 
react adversely to the drugs. Thus, in this manner, technology could help improve compliance to 
set regulations, which will help increase the speed of clinical research and the timely address of 





This study design used was the qualitative design, and it entailed a comprehensive review 
of the literature. The literature was sourced electronically by doing an electronic search of 
reputable medical databases such as PubMed and Cinahl. The literature included for use in the 
review were published in the last five years. The timeframe was selected because it allowed the 
inclusion of the most recent research. The information sources were mapped using keywords and 
phrases. These keywords and phrases included: the scientific research process, the evolution of 
clinical trials,  virtual clinics, and COVID-19, challenges in recruitment and retention of clinical 
trial subjects, use of electronic data sources in clinical trials, evaluating clinical performance, 
artificial intelligence technology, and medical diagnosis and prediction, and effects of COVID-19 
epidemic on clinical research. The study did not include human participants, which exempted it 
from the IRB's requirements to protect human subjects. 
The data collected was analyzed thematically to ensure consistency in reporting. It entailed 
coding and categorizing the data found in the selected articles. Each category was subsequently 
compared, and further analysis and synthesis were completed. The approach was appropriate 
because the data was sourced from different studies with varied methodologies. This also 
necessitated the use of a qualitative approach for this study and analysis of data.  
The qualitative design based on a literature review was ideal because it transcends existing 
knowledge's strengths and weaknesses and develops a more meaningful understanding. The review 
was conducted to evaluate the rigor of clinical research processes, the role of technology, and how 
technology could be integrated into fast-track clinical research during the COVID-19 pandemic. 
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The goal was to summarize past research and present a current state of knowledge that calls 
attention to the integration of technologies into future clinical research. 
2.1. Problem Formulation Stage 
This section provides focus and boundaries for the literature review process by defining 
the research problem and interest variables. The problem addressed in this literature review was 
the disruption of clinical research processes following the outbreak of the COVID-19 pandemic 
because of the lack of supporting technologies that would facilitate safe and timely clinical 
research processes. Variables of interest for the project included the current state and process of 
clinical research and the role of technology in facilitating the process. The purpose of this scholarly 
project was to identify how the adoption of technology in clinical research processes could 




3. Literature Review 
3.1. The Basis of Clinical Research: Planning 
Studies show that the clinical research process in its current state is intensive and laborious. 
Weintraub (2020) revealed that the lengthy processes and need to adhere to the set regulations that 
govern clinical trials that involve live animals or human beings slowed down the drug development 
process. The study by Segelov et al. (2020) also revealed that the outbreak of the COVID-19 
pandemic had hampered these clinical trial processes. To fully understand the relevance of these 
findings, one needs first to assess the process of clinical research. According to the Nation Institute 
of Health (NIH), clinical research includes patient-focused research, well-being research, 
epidemiological and behavioral research. Clinical research involves human subjects or utilizes the 
materials from human subjects, such as samples of their tissues or behavior. Most clinical research 
aims to study the reaction of human subjects to the investigational product, including the 
absorption, distribution, metabolism, and excretion of the product under study and its safety and 
efficacy ("What is Clinical Research?" 2020). Throughout the entirety of a clinical trial, human 
subjects are carefully monitored, and most times, blood samples are collected at specific intervals 
as defined in the clinical trial protocol. The data generated from clinical research are analyzed to 
determine whether the participants' reactions warrant their continued participation in the study. 
The end goal is to better patient care by creating new, safe, effective, and cost-effective drugs for 
global production. The NIH asserts that designing processes that maximize efficiency in 
preventing, diagnosing, treating a disease is an immense contribution toward meeting the end goal. 
However, few studies have investigated how to fast track this process. According to a study by 
Eichler and Sweeney (2018), one of the future challenges that are likely to impact clinical trials is 
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the lack of technologies that would aid the recruitment, monitoring of participants, collecting data, 
and reporting of patients' reactions remotely. Most of the studies, including Eichler and Sweeney 
(2018), only cite this as an issue and do not provide solutions to address it. This has resulted in a 
dearth of information about the technologies that would lessen the burden of conducting clinical 
research.     
3.2. Data Collection 
Another vital issue that has been identified is the collection of data, more so with the 
outbreak of the COVID-19 pandemic. The study by Sessler and Imrey (2015) revealed some of 
the critical issues that limit clinical trials' success are the study design and data collection methods. 
The issues include ineffective participant recruitment strategies that limit the data collection 
process. There is high participants’ turnover and the cost implications are high. According to the 
NIH, clinical trials help collect data on the safety and effectiveness of products under study (What 
Are Clinical Trials and Studies? 2020). Clinical trials on human subjects result in the discovery of 
knowledge of new treatments and behavioral interventions. The experimental treatment studies in 
human trials usually entail assessing new novel vaccines, nutritional choices, drugs, nutritional 
supplements, and medical devices. To conduct clinical trials, approval from the health authority 
and ethics committee is essential. The approval of a clinical trial is done after evaluating the risk 
and benefit ratio of the trial. 
Moreover, clinical trials vary in size and cost depending on the number of research 
participants recruited. Clinical trials happen in phases that necessitate the use of multiple trial 
centers, which increase the cost of conducting them. Besides, in phases one and two, twenty to 
three hundred research participants make the process costly6. Breton, Lamberti, Dion, Getz (2020) 
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also reveal that the COVID-19 outbreak has disrupted the data collection processes because of the 
virus's infectious nature and high fatalities for vulnerable patients. However, these studies do not 
explain how these challenges could be addressed, which leaves clinical researchers unable to 
address them in the research process.   
Currently, there are limited studies on the technologies that fit the needs of different clinical 
trials. When classified based on purpose, clinical trials give rise to the following experiments; 
prevention, screening, treatment, life value, genetic, fixed trials, and adaptive clinical experiments. 
Prevention clinical trials involve study trials to protect people who have not contracted the disease 
from contracting it. The study approach involves the use of vaccines, micronutrients, vitamins, 
lifestyle changes, and drugs. Screening clinical trials intent to research and develop better and 
sustainable quality protocols for diagnosing a particular condition or disease.  Treatment clinical 
trials aim to assess experimental drugs, new surgery or therapy approaches, and a new combination 
of drugs to find if it is effective in human subjects7. There is a need to define the technologies that 
could improve these different clinical trials. The current mostly manual process limits the 
effectiveness of these processes in the light of the COVID-19 pandemic. Besides, the involvement 
of humans and live animals in clinical research further complicates the process in the wake of the 
COVID-19 pandemic. The virus is spread through an infected person or contact with a 
contaminated surface. In clinical research, clinicians and nurses are mostly expected to be near the 
patients under study, which puts them at considerable risk. 
Overall, the application of technology in the clinical research process will help address 
most of these issues. The current studies on the clinical research process do not address technology 
in the research process despite the numerous challenges identified and the laborious process. The 
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studies also reveal that there is also a general lack of awareness about the type of technologies that 
could be used to overcome the challenges caused by the COVID-19 pandemic regarding the 
recruitment of participants, collection of data, and reporting of patients' reactions to drugs under 
study.  
3.3. Recruitment of Participants 
The selection of study participants is also another critical issue that could be addressed using 
technology. Clinical trials that entail drugs are usually categorized into four phases, with each 
having different participant sizes.  Phase 1 studies usually test the drug's harmless dosage and its 
side effects in a few 20 to 100 healthy research participants. Phase 2 needs more human subjects, 
usually 100 up to 300 participants, to observe any harmful effects. Phase 3 studies are done to 
assess the therapeutic effect of the drug, and it is conducted on larger populations, usually 300 to 
3000 individuals and in different regions and countries. Phase 4 is typically known as the post-
marketing stage, where the FDA approves a drug. At this point, it is ready to be prescribed to the 
public, and anyone with the condition may take it. The current approach to participant selections 
is randomization. It is applied in phase three trials, randomly choosing the research participants8. 
Research participants are randomly given the existing drug and the drug under investigation, 
making the study a double-blind clinical trial. Double-blinded trials help to eliminate bias during 
the interpretation of results. 25% to 30% of drugs under clinical trials proceed to phase four. Phase 
four clinical trial is usually termed as post-marketing surveillance and post-marketing after the 
country's approval to assess the drug side effects. As such, the process of drug development and 
testing to ensure its safety once rolled out to the public is laborious. It is prone to human errors 
that lengthen the experimental process and increase associated costs. 
 
8 Hall, K. T., & Loscalzo, J. (2019). Drug‐placebo additivity in randomized clinical trials. Clinical Pharmacology  
& Therapeutics, 106(6), 1191-1197. 
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According to Kadam et al. (2016), there is a heavy burden on clinical research professionals 
identifying, consenting, recruiting, and enrolling a patient. Recruiting and retaining research 
participants is a key element for successful clinical research. Recruiting the right research 
participants and retaining them until the completion of the clinical trial ensures there will be a 
complete and accurate data set to be used and analyzed in scientific and regulatory decisions. 
However, clinical research professionals face the challenge of recruiting and retaining research 
participants (Kadam et al., 2016). Failure to recruit participants effectively and retain them until 
the clinical trials are finished is a major reason for the termination of clinical trials. According to 
the Clinical Trials Database, 55% of the trials were terminated due to a low accumulation rate (the 
minimum number of participants needed during a particular clinical research phase). The average 
enrollment efficiency of phase three and four being less than 40%9. Most clinical trials fail to enroll 
research participants within the proposed timeline, leading to the extension of the research study 
duration and the addition of study sites10. As such, the failure to recruit and retain the required 
number of research participants is also a major clinical trial problem. Foge (2018) also explained 
that the few retained participants will not answer the original research questions appropriately, 
which results in the delay of the study and incomplete/unevaluable data. In tackling the issue, 
technology benefits many clinical research professionals by saving enormous time in identifying 
the right patient for a study. Proper implementation of technology software could help patients by 
scanning electronic medical records and quickly eliminate many patients whose medical history 
does not meet the exact inclusion and exclusion criteria. 
 
9 Fogel, B.D. "Factors associated with clinical trials that fail and opportunities for improving the likelihood of 
success: A review" Contemp Clin Trials Commun. 2018 Sep; 11:156-164 
10 Fogel, B.D. "Factors associated with clinical trials that fail and opportunities for improving the likelihood of 
success: A review" Contemp Clin Trials Commun. 2018 Sep; 11:156-164 
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Clinical research is changing due to the advancement of health care systems. Currently, the 
design of clinical trials is multifaceted, refined, and modernized. These designs are put in place to 
find the therapy that will be useful in the treatment and management of conditions that have no 
treatment or those conditions that have shown little improvement with previous treatment lines. 
Most treatment designs utilize the inclusion criteria, which are more specific, rigorous, and 
tightened (Eicher et al., 2016). Inclusion criteria are intensive, leading to more prolonged 
recruitment, necessitating protocol modification to recruit more research participants and study 
sites. More than 40% of clinical research trials modify the research protocol before the first subject 
visit, which delays the trials by four months. Multiple studies enrolling from the same patient 
population may also create unanticipated competition that could slow research accrual rates. In 
reality, scanning through every patient’s medical history is burdensome and eats up a significant 
amount of time. There is a need for technology that could perform  a complex calculation to 
identify the right patient for a specific study while minimizing potential human error that could 
have existed when done manually. 
The nature of the population influences the selection and retention of research participants. 
A population's education level, socioeconomic status, sociocultural understanding, and clinical 
research will impact the population's responsiveness to clinical trials. African Americans were the 
biggest victims in the Syphilis Study at Tuskegee, as they were easily misled about special free 
treatment and did not consent to the study. Even after treatment was found for syphilis, the study 
continued for several more years. As a result, the death rate was twice as high in men with 
syphilis11. As such, African Americans may not be as responsive in participating in a clinical trial 
due to the historical mistrust. Although the Belmont Report, which was created in 1978, provided 
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three fundamental ethical principles for all human subject research, it did not erase the tragedy of 
systemic racism.  
 Clinical research study staff play a vital role in research participants' selection through 
research participants' involvement. Study staff is trained to understand the research protocol and 
effectively communicate with the patient, understand the challenges the research participant is 
going through, and provide encouragement to the research participants. Therefore, study staff 
could promote the retention of research participants, which would be a positive factor in clinical 
trials. For research professionals to reduce dropout among research participants, professionals 
should provide proper guidance and coach the research participants explaining in detail the risks 
of participating in trials and the risk mitigation plans. This would help reduce the dropout rate 
since the research participants will be aware of what they are subscribing to without pressure or 
coercion. For research trials that require additional visits for tests and procedures, the research 
investigators should provide incentives to the research participants to compensate them for the 
inconvenience they have been subjected to by attending additional visits (Torous et al., 2018). The 
clinical research study site should provide a positive environment to promote research participants' 
retention. The staff at the site should employ a courteous and friendly approach to the participants. 
By observing all these measures, the research participants' dropout rate will be minimized. 
Technology could help save time that could be utilized by clinical research professionals by 
providing a better bedside manner instead of being distracted by trying to remember which 
paperwork is needed and what the protocol dictates. 
3.4. The Effect of COVID-19 on Clinical Trials 
The new coronavirus SARS-CoV-2 (COVID-19) disease originated in Wuhan (China) in 
December 2019, and it spread worldwide. The disease caused many deaths, coupled with a 
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negative effect across all sectors globally; the healthcare system is one of the majorly affected 
sectors. The Coronavirus spreads through droplets, and it is highly contagious, where severe illness 
due to this disease demand hospital admission. The effects of COVID-19 in the health sector 
include the hospital measures to keep patients away from the hospital, where only patients with 
acute and terminal diseases like cancer and heart diseases are admitted. COVID-19 has affected 
the ability to conduct trials in safe and effective ways. The predisposition of the elderly to the virus 
has a more negative impact, especially in clinical trials, which usually rely on the elderly. Due to 
this pandemic, thousands of trials have been suspended due to the difficulties of conducting 
research studies with the lockdown in place. COVID-19 has placed much pressure on the clinical 
research field (Segelov et al., 2020). 
 In the effort to minimize research participants in visits, most of the study sites were closed. 
Many research participants also dropped out of the research study to take preventive measures 
towards the pandemic. As such, the research professionals were forced to look for other research 
participants. This demands the amendment of research protocol coupled with increased cost and 
ethical challenges. The redirection of resources to help fight the COVID-19 pandemic also 
imposed some challenges to the clinical research field12. 
Most governments currently have issued permission to continue with the clinical trials but 
with stringent adherence to the laid down protective measures. The laid down guidelines on how 
to conduct trials during this pandemic moment highlights the need to adapt trials to accommodate 
the pandemic. The guidelines also highlighted the need for the clinical research authority's 
flexibility in amending the protocols, deviations, and clinical data during this period. The clinical 
trials with the following characteristics are more likely to be delayed with this COVID-19 
 
12 Weintraub, K (2020). Covid-19 slows drug studies, curbs clinical trials. 
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pandemic; clinical trials that involve vulnerable populations as research participants have to be 
delayed until the pandemic is managed. Vulnerable individuals include the elderly, the 
immunocompromised, and patients with pulmonary diseases (Weintraub, K. 2020). 
Endpoint clinical trials that need assessment in person or through hospital equipment such 
as CT and PET scans have to be delayed. Hospitals currently are only accessible to individuals 
with terminal diseases or individuals with emergency cases; the trials that utilize the hospital have 
to be delayed.  Clinical trials that require therapy to be administered in the hospital, such as 
immunosuppressive therapy clinical trials have to be delayed due to the currently limited access 
to the hospital. Trial sites located in places with a high density of the Coronavirus disease translate 
to the study's delay. The clinical trial study staff and research participants cannot effectively work 
harmoniously to realize the study's objectives due to the prevailing COVID-19 disease13. 
The long-standing side effects of the COVID-19 disease to the clinical research field may 
be delayed trials due to the restrictions put in place will increase the cost of the trials. The 
implication of COVID-19 in clinical research will be felt in repaired documentation, clinical trial 
protocol amendments, data collection, and clinical trial results interpretation. The research 
participant's risk of contracting the COVID-19 disease is also highlighted14. If the patient 
succumbs because of the Coronavirus, the validity of the clinical trial results will be affected 
because of reduced the number of participants needed for an effective clinical study. Research 
participants who succumb are removed from the trials, and this, as much as it is not a willing 
dropout decision, will reduce the number of research participants. Failure to have the required 
number of research participants will impact the clinical trial's potential to achieve statistical 
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significance. The cost of recruiting other research participants to achieve the threshold required 
number is increased. The associated delays also alter clinical trial protocols15.  
Technology could act as a potential gatekeeper in avoiding human errors during a clinical 
trial. When a clinical trial is conducted, there is always a constant evolution to the protocol as a 
reaction to an event that transpired .Therefore, a protocol will always be continuously amended 
once it has been reviewed by the regulatory authorities like the IRB (Insitutional Review Board), 
DSMC (Data Safety Monitoring committee), and so on. On top of that, once a protocol is amended, 
other regulatory entities must be immediately informed of new changes to review and approve the 
change for human protection before a trial can be continued. Clinical research professionals must 
stay on top of all new changes, review and study what the changes entail, and apply the changes 
during the conduction of a trial. In reality, human power is limited, and keeping up with constant 
new changes is difficult – potentially causing protocol deviations and inaccurate data reporting. 
New approaches to ensure that clinical research continues despite the pandemic have been 
put in place by most departments and organizations conducting clinical trials. Approaches to 
conducting remote visits for research participants are already in place. Research participants can 
access their stipulated clinical visits through telehealth and home-based testing and monitoring 
technology. The approach employed to ensure clinical research continuity despite the pandemic 
provides courier services to pick up and deliver the research participant sample and investigational 
products. The approach ensures that the lockdown measures, as well as the social distancing rules, 
are observed. The clinical trial research updates are made available to the research participant 
through telephone, email, or elect record portal home-based study (Kellar et al., 2017). The 
strategy to develop optimally safe approaches for the research participant was done according to 
 
15 Weintraub, K (2020). Covid-19 slows drug studies, curbs clinical trials. 
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the FDA report. FDA issued the guideline to the researchers and clinical trial sponsors that they 
should protect the safety and welfare of clinical trial research participants by continuing with the 
trials, as per the clinical study trials or discontinuing the clinical trial use of products by the 
research participants (Da Silva et al., 2018).  
For the clinical research field, the limited resources and inadequate and incomplete data 
generated from halted projects will significantly impair the clinical research movement post-
COVID-19. The lack of complete data may lead to poor decision making since data usually make 
the basis of decision making in the clinical research field. The CRO increase of pandemic 
possibility planning will increase the cost of conducting clinical trials post COVID-19. 
3.5. Modernizing the future of Clinical Research 
Modern electronic technology is an essential tool in clinical research tool (Kellar et al., 
2017).  Electronic technology can be utilized to determine the viability of conducting trials and 
patient population through powerful computing and calculation in predicting the patients that meet 
study participation criteria. Electronic technology can be leveraged to identify potential research 
participants for a specific trial, find information about the current trial, and link with resources to 
reach out to the desired population. Some electronic technology utilized in clinical research 
includes; electronic health records, payers' data, insurance databases, and social media platforms 
(Parab, et al., 2014). When recruiting participants through electronic technology, professional 
websites can disseminate information about the current or prospective clinical trials without 
disclosing the details. (Mc Cord et al., 2019). Artificial intelligence as a form of modern 
technology can also optimize clinical research through its utilization in clinical trial design, 
selection, and monitoring of research participants under study. Technology, when designed 
correctly according to the need for a clinical trial should be able to identify potential patients that 
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are hard to find through internal electronic medical records, social media, or other electronic 
advertisements. Once a patient has been correctly identified, technology could further assist the 
progression of a patients’ well-being throughout a clinical trial via direct data reporting on an 
electronic platform such as EDC (Electronic Data Capture) to ensure that the patient is not injured 
during the trial. Sponsors typically are required to travel to a site to monitor the a patient’s 
progression which has been recorded by clinical research professionals. In reality, this requires 
elaborate time planning, and scheduling and sponsors would not have direct access to crucial data 
24/7. If and when a site implements proper electronic data capture software, all pertinent 
information would be recorded directly online and saved in a secure cloud. As a result, this method 
provides a much more secure pathway of accession and gives  easier access for the sponsor through 
24/7 access. The FDA recognizes the importance of remote monitoring and direct online 
documentation, which resulted in new guidelines of the Code of Federal Regulations (CFR) 21 
part 11which states that all potential electronic software must be equipped with an audit trail as 
real-time information are recorded. They are also stamped with time, date, and the user responsible. 
Another avenue that was implemented from CFR 21 part 11 also includes the legality of an 
electronic signature in which a delegated user can sign electronically. This is a significant change 
for clinical research professionals as they do not have to waste time by having to sign a document 
with wet ink, scan the document, print it, and store it. By law, any direct source documents in the 
form of a physical paper must be kept in storage for at least two years. Changing the mode of 
documentation from paper to electronic, it saves time as well as significant cost to buy paper, run 
a printer, and rent a storage. 
Incorporating modern technology into the clinical research field will bring forth new 
perspectives on how clinical trials are conducted and promote quality, up-to-date clinical research. 
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Electronic modern technology makes clinical research work easier by saving a considerable 
amount of time for all parties involved in the clinical research process. Electronic technology will 
help to minimize patient visits and make clinical research easy and cost-effective. Hypothetically 
speaking, if the regulations allow for it – virtual visits should happen. Patients wouldn’t feel as 
pressured to come to the office to perform necessary assessment when it can be done online thus 
increasing engagement and compliance. The time utilized commonly by research participants to 
visit the clinics is reduced (Torous et al., 2018). Electronic technology can be utilized to determine 
the viability of conducting trials and patient population. Electronic technology can find eligible 
research participants for a specific trial, find information about the current trial, and link with 
resources to reach out to the desired population. Some Electronic technology utilized in clinical 
research includes electronic health records, insurance databases, and social media platforms. When 
recruiting participants through electronic technology, professional websites can disseminate 
information about the current or prospective clinical trials without disclosing the details. 
Financially speaking, virtual visits saves money for both sponsors and patients as patients would 
not have to waste time and money for transportation, and sponsors would not be pressured to offer 
stipends to get patients interested in a clinical trial. 
Technology has also increased patient participation and helped them feel more involved in 
the research process (Torous, et al., 2018). Modern technology will help curb the traditional 
method limitations, including the cost and time spent designing the study, including the research 
participants' selections and analysis and interpretation of results. Adopting modern technology will 
improve the clinical trials' efficiency and productivity, thus enabling optimal clinical research, and 
the aftermath is improved and quality patient care. 
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The new technology that can be adopted in clinical research includes wearable devices, 
virtual clinics, and remote monitoring. These modern technologies adopted in clinical research are 
vital since they aim to make clinical trials patient-centered (Lee et al.,2018). Ensuring that modern 
technology incorporated into clinical research yields optimum results, social media can provide 
increased opportunities for patient engagement. The 21st century have changed the way people 
live, and most people have some form of electronic devices that regularly connects them to the 
world. Clinical research stakeholders should recognize this and capitalize on the patients’ time in 
participating for a clinical trial. Wearable devices can provide clinical trials researchers with a 
clear and detailed outlook of participant well-being by taking all research participant exposures 
and how they affect research participant well-being. It offers detailed information on the impact 
environment has on the research participant's treatment.  Incorporating new technology in clinical 
research translates to increased productivity and participant engagements, trial management, novel 
outcomes, and reduced patient burden. Through applying the new technology in clinical research, 
next-generation clinical trials can be done effectively with low cost and high-quality data. 
The assessment of activity and behavior of clinical research participants is one method that 
enables the collection of detailed and frequent information. The use of modern technology in 
research participants' responses measurements is relatively cheap compared to traditional methods 
that entail participants coming to the office for a quick survey. Besides, it captures all the 
information which cannot be captured in traditional clinical trial measurement methods that is done 
on paper. Miniature and more sophisticated sensors could provide the increased use of these 
technologies in clinical research trials. Sensors are used to develop digital signatures that 
characterize different research participants' responses and pave the way for timely interventions 
(Lee et al., 2018). 
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Technology can be utilized in clinical research to match prospective research participants 
in a proposed clinical trial. The devices that allows for remote access and virtual visits make 
clinical trials easy since they enable researchers to reach a much wider audience than they could 
in traditional methods. Clinical trials involving a small number of research participants can be 
carried out successfully through technology. Phones with apps utilized during trials are offered to 
the research participants to enable follow up during the study period. Patient enrollment on time 
is increased by 50 percent, and there is a generation of a diverse pool of participants and insightful 
clinical endpoints (Torous et al.,2018).  
Electronic health records (EHR) are instantaneous digital records comprising patient 
diagnoses, medications, laboratory examinations, prescribed drugs, and clinical encounters. EHR-
based clinical data plays a vital role in clinical trials. EHR is utilized by researchers in planning 
and designing clinical trials, site start-up, study execution, data collection, determination of trial 
representativeness, and clinical events follow-up (Cowie et al., 2017). Electronic health records 
data can pinpoint the effect of inclusion/exclusion criteria on the research study participants' 
recruitment rates at the site level more accurately by highlighting certain patients that has all the 
conditions listed on the inclusion/exclusion list. Researchers use electronic health records data to 
determine the phenotype of clinical research study populations. Clinical research trial sites and 
health systems with many prospective participants can be identified by analyzing electronic health 
systems data. Electronic health records data can inform the trial sample size and statistical testing 
considerations in clinical trials.  Electronic health records data are changing how clinical trial 
procedures are planned and polished.  
Electronic Health Monitoring is another aspect of modern technology integration into 
clinical research. Electronic health monitoring enables researchers to collect data on research 
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participants without incurring extra costs (Ellar et al.,2017). An example of electronic health 
monitoring in clinical research is the Apple company earbuds, which observe the research 
participant's vital signs. Clinical researchers can utilize this to monitor the research participants' 
responses to the products under trial (Philip et al., 2017). The earbuds observe the research 
participant's heart rate and other vital signs, and this is vital in clinical trials in remote monitoring. 
Besides the earbud, various applications and devices in the market are capable of tracking heart 
rate, blood pressure, and other vital signs. These applications are vital to clinical researchers since 
the data obtained can be analyzed and used based on clinical research trials. The applications have 
the advantage of enabling researchers to access data with minimal costs since the regular visits to 
the site to collect data are minimized. The challenge posed by the monitoring devices and 
applications to the clinical researchers is the standardization of different types of devices and 
applications.   
The future success and efficiency of clinical research and clinical trials are heavily 
dependent on the utilization of emerging technology. The technology to be incorporated in the 
future should promote immersed treatment to the clinical trials patients (immerse treatment entails 
gathering data that allows researchers to help participants overcome worries or concerns that might 
limit the study process), facilitate continuous patient data collection, allow researchers to ensure 
that adaptable trials are in place, and support the next-gen support ecosystems. Immersed treatment 
entails the use of technology to offer therapeutic solutions with minimal pain. Clinical trials usually 
accompanied by painful procedures and medications usually face high rated research participants' 
noncompliance. By integrating the technologies that ensure research participants encounter 
minimal or no pain during the trials, the quality, efficiency, and productivity of research will 
increase (Ellar et al.,2017). 
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Ensuring that modern technology incorporated into clinical research yields optimum results 
through social media since social media provides increased opportunities for patient engagements. 
Incorporating new technology in clinical research translates to increased productivity and efficacy 
in patient engagements, trial management, novel outcomes, and reduced patient burden. Through 
the application of new technology in clinical research, next-generation clinical trials can be done 
effectively with low cost while obtaining high-quality data (Ellar et al.,2017). 
Technology advancements that promote immersed treatments include the use of virtual 
reality technology and comprehensive reality technology. Applied virtual reality utilizes a 
computer-generated platform to manage prolonged pain and severe pain and anxiety. Virtual 
reality is shown to have the ability to decrease pain scores in hospitalized patients by 24%. This 
technology enables patients to have pain-free treatment and increases their compliance (Li et al., 
2017). In future clinical research, comprehensive reality technologies will enable regular 
procedures, improve obedience, and help achieve improved results. Patients would have an easier 
access and more convenient route of doing procedures or assessment requirement from a clinical 
trial at the comfort of their own space instead of having to travel to the office. Clinical research 
professionals can stay more engaged by sending out friendly reminders electronically (text 
message, email, or other preferable methods of electornic communications). Comprehensive 
reality technologies help educate research participants about their conditions and treatment plans 
together with upcoming techniques. Comprehensive reality technology is, therefore, a vital 
component of inpatient and research participant care.   
Technology in the future will revolutionize clinical research by enhancing more use of 
wearable technological devices by research participants in clinical trials. These wearable 
technological devices track the research participants' sleep patterns, exercise, and heart rates. The 
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devices will enable researchers to access real-time and accurate data from the research participants' 
passively with their consent more easily. In-built sensors placed in phones, clothing, and domestic 
devices can quickly and continuously gather data from research participants, making the clinical 
research data collection easy in terms of cost and time used (Majumder et al.,2017). 
Miniature, wireless, self-powered, passive sensors comfortable to the research participant 
can be placed on the research participant's body to improve the data's quality. Temporary digital 
tattoos (thin layer of films that resembles a tattoo, equipped with digital chips underneath) on 
research participant bodies can measure drug release to the body, ECG measurement, and fall 
detection. Wearable devices can provide clinical trial researchers with a clear and detailed picture 
of a patient's well-being by capturing all research participant exposures lifetime (exposure to risk 
factors for an ailment or disease) and how they influence a person's health (Bhelkar et al. 2016). 
During clinical trials, the environment affects the research participants' outcomes. As such, 
researchers could also assess the environmental impact on the outcome using air-particle sensors 
and account for these environmental effects in the clinical study outcomes.  
Electronic health records help research participants quickly access their records at any time 
from their homes' comfort without necessarily traveling to the clinic. However, electronic health 
records are faced with the challenge of upholding transparency during the collection and analysis 
of research participant data (Kruse et al., 2017). The transparency in this context refers to the direct 
uses of research participants' data and their anticipations concerning the full band of probable 
examinations provided. The data's access and utilization will raise many ethical questions about 
using the data obtained and the extent to which the researchers can utilize the data obtained. Some 
of the questions expected to emerge include; are the clinical researchers utilizing the data 
accountable for properly sharing real results to the research participant even if the data's initial 
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usage is dissimilar? Another question that will emerge is, do the researchers inform the research 
participant of new disease diagnosis that came up during the clinical trials? Will the research 
participant be interested to know about the diagnosis? What if the diagnosis turns out to be false 
negative after the research participant is informed?  
 Adaptive clinical research updates are activities done to modify the clinical trials to 
increase or meet expected clinical trial productivity. These adaptive trials can advance clinical 
experiment accomplishment rates and considerably reduce periods and costs (Li et al., 2020). 
Electronically captured data is vital in promoting the implementation of adaptive updates in 
clinical research. Electronic modern technology allows faster analysis of the captured data, 
allowing adaptive changes to be made promptly. Adaptive clinical trial updates made possible by 
incorporating modern technology include the addition of research participants to ensure that 
statistical power is not lost. Statistical power is lost when research participants drop out of clinical 
trials due to diverse reasons. The dropping out can leave the research study with few research 
participants who cannot generate data with statistical significance.  
Accommodating relocation of research participants is vital in an attempt to meet the 
preferred treatments at the course of the study due to the collected data. Simply put, once a patient 
has been identified electronically, technology should be able to compute more powerful 
randomization, or randomly assigning patients to drugs or placebo – providing each patient with 
treatment that could strengthen a clinical trial design. Simply speaking, when a randomized trial 
is conducted properly, randomized trial have the highest level of experimental validity. Proper 
randomization allows a trial in ensuring equivalent treatment, control groups, and quality control 
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over the data and timing of the intervention16. The use of adaptive updates in clinical trials will 
reduce the available clinical trial cycle time by propelling whether to continue with the trial or 
terminate it. The adaptive updates also allow for more relevant analysis time points (Li et al., 
2020). Adaptive updates also research participants' exposure to side effects, increasing the research 
participants' compliance and reducing the dropout rates, thus improving the research participants' 
retention17. Experiments illustrate that 29% of all research participants quit after complying with 
trials due to their fears about side-effects (Li et. al., 2017).  
Technology could improve future clinical trials by connecting research participants and 
researchers. The connection could promote more effective communication across the clinical 
research process. There is greater trust and transparency throughout the clinical research trial when 
there is communication between researchers and research participants, improving research 
participant engagement and retention. The connection between these two parties can be made 
through social media platforms. Using technology to better future clinical research is possible by 
using digital agents to recruit eligible research participants and educate them about the clinical 
trials (Ellar et al.,2017).  
 Electronic software can improve research participants' experience during the clinical trials. 
The digital agent will assess whether the research participant is qualified for any suggested clinical 
experiments. The agent completes the administrative onboarding process once consent is obtained. 
Artificial intelligence, together with machine learning, enables the development of intelligent 
digital agents. In future clinical trials, digital agents will be trained to conduct multifaceted 
 
16 Retrieved from: https://www.hydroassoc.org/research-101-an-explanation-of-clinical-trials-
design/#:~:text=If%20done%20correctly%2C%20randomized%20clinical,and%20timing%20of%20the%20interventi
on. 
17 Li, L., et al. (2017). Application of virtual reality technology in clinical medicine. American Journal of Translational 
Research, 9(9), 3867. 
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intellectual tasks, such as defining the research participant's suitability for a clinical trial (Beck et 
al., 2020). By facilitating fast, well-organized trial finding, and onboarding, these digital agents 
can quickly and efficiently recruit research participants.  The challenge of clinical trial delays due 
to recruitments will be significantly reduced18.  
The future of clinical research data collection and analysis will be better through the use of 
modern technology.  Clinical experiments history is traced using Blockchain technologies 
(Benchoufi et al., 2017). Blockchain technology is a decentralized internet platform where “any 
service or software relying on trusted third parties can be built in a transparent, decentralized, 
secure “trustless” manner, allowing users to have a high degree of control over autonomy and trust 
of the data and its integrity”. As a result, decentralization applications ensures “traceability, 
prevents a posteriori reconstruction (beautification of data) and allows for securely automating the 
clinical trial, and at the same time the technology also ensures fine-grained control of the data, its 
security, its shareable parameters, for a single patient or group of patients or clinical trial 
stakeholders” (Benchoufi, et al., 2017). Clinical research networks such as researchers and 
research participants, together with sponsors, utilize decentralized applications that push and read 
data to and from the blockchain network. Decentralized data repositories in clinical research can 
ensure better security of data, ensuring appropriate data privacy and ownership, and preserving 
clinical experiment data accuracy (Diebolt et al., 2019). This, in turn, lays a solid base for online 
supervisory authentication of clinical trial results meaning data recorded is up to par with 21 CFR 
58.130 (e) ALCOA-C (Attributable, Legible, Contemporaneous, Original, Accurate, Complete) 
Good Documentation standard. Ownership of research data should employ transparency by 
remaining in the research participants' hands. It gives research participants more control over their 
 
18 Beck, D., et al (2020). Increasing access to clinical research using an innovative mobile recruitment approach. 
Contemporary clinical Trials communications, 19, 100623. 
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collected data. Blockchain and cryptocurrency facilitate the trading of data for payment. A fast 
and effective system capable of processing large constant streams of data can better the clinical 
research status.  
Human error encountered during data collection could be reduced through electronic data 
capture. The increased artificial intelligence developments permit immediate data gathering and 
handling for independent representatives and connected devices (Diebolt et al., 2019). Smooth 
data management should reduce the traditional data collection disadvantages of an increased 
amount of period and laborious effort in clinical study management processes. The gathered data 
could permit researchers to develop opinions on research participant well-being.  
Regular clinic visits will soon be reduced in most clinical experiments.  Clinic visits can 
be replaced by incorporating virtual communications, connected wearable devices, and 
improvements in-home delivery (Park et al., 2018). The AOBiome Stage 2b trial acne study 
eliminated site visits. The study selected more than eight thousand research participants, but it 
registered 372 patients for a 12-week study. It also experienced improved inclusivity (more people 
in more areas regardless of socioeconomic status) in enrollment matched to traditional trials. 
Research participant-centered connected devices will play a vital role in future clinical research. 
Connected devices used by research participants like wearable devices, nanotech, extended reality 
devices, virtual assistants, and bots are precisely utilized to capture data during virtual schedules. 
Extensive and increased embracing and virtual communication facilitate distant communications 
between clinicians and their clinical trial research participants (Diebolt et al., 2019). 
Advances in the cold cable, three-dimension printing for therapeutic devices, and the 
distribution drones could promote effective home delivery. It could promote the direct distribution 
of trial materials to the research participants that would previously have been given to patients 
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during consistent clinic appointments (Park et al., 2018). The change from site visits to research 
participants' households should escalate patient loyalty and lessen patient dropout due to the 
decreased research participants' frequent travels to the clinical research clinics. The cost of 
conducting virtual study site trials is could be reduced compared to traditional clinical setups, 
labor-intensive, time-consuming, and costly.  
Incorporating algorithms in clinical research will enable easy data analysis from a 
worldwide, homogenous, safe scientific database. This will approximate the journeys of virtual 
research participants (participants that are doing clinical trials from the comfort of their own space) 
through clinical experiments and precisely forecast the trial outcomes  (Diebolt et al., 2019). The 
use of Algorithms in clinical research trials is currently evident in clinical trials like the HumMod 
physiological model, and existing indication from companies such as Flatiron and Medidata 




4. Results and Discussion 
4.1. Planning Phase 
The review of the literature revealed that the clinical research planning process is rigorous, 
time-consuming, and expensive. Researchers have to comply with the regulations and warnings 
issued by organizations such as the FDA regarding participants' safety and accurate and timely 
reporting of adverse events (Browning, 2019). The review also revealed the need for regulatory 
support in enhancing clinical research during the COVID-19 pandemic. The FDA has been 
relatively quick and responsive in amending its policies and guidelines at the pandemic's dawn, 
allowing many organizations to implement remote software quickly. However, the concern lies in 
its ethical and safety concern: does remote deployment prove to be just as safe and confidential as 
visits done in the office directly (Angeletti, Chatzigiannakis, and Vitaletti, 2017). Unfortunately, 
there is not much more information available on the impact on full remote visits without the FDA's 
full support. Diebolt et al. (2019) assert that the full implementation of an entirely virtual visit is 
the key to advancing clinical trials. The future of clinical trial is already here; however, it would 
not be fully implemented without a conscious and concerted effort from both industry and 
regulators to carry the momentum forward. 
According to the study by Browning (2019) clinical researchers have to seek the approval 
of the relevant authorities, which entails meeting the minimum requirements. Bourin (2017) 
explains that the planning stage presupposes two requirements: the formulation of a clear, precise, 
and relevant therapeutic question and the certainty that the reply to this question has not already 
been given in earlier studies. This is in addition to meeting the minimum requirements set by the 
approving bodies such as the FDA. The current state of clinical research planning and the need to 
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achieve these goals make it a laborious and expensive process. the conventional face-to-face 
planning activities prolong the phase and waste a lot of time. For example, a study by Aimee et. 
al. (2015) revealed that conventional approaches include using newspaper or radio advertisements 
to recruit participants, mail, or telephone calls are used to conduct follow-up assessments. These 
processes are costly and time-consuming. Technologies such as mobile phones and social media 
platforms have the potential to reach a wider audience and are relatively affordable. According to 
Aimee et. al., (2015), approximately 90 percent of all adults in the US use the internet and own a 
mobile phone. Moreover, 74 percent of adults in the U.S use have social media pages on platforms 
such as Facebook, Instagram, and Twitter. Besides, while young people are more likely to be using 
e-technology older adults are increasingly adopting it in their lives with 77 percent of older adults 
aged above 65 owning smartphones. As such, these technologies (smartphones and the internet) 
provide clinical researchers with a wide audience reach that allows them to communicate their 
study topics and purpose and gather feedback. It also allows them to reach out to millions of people 
and low costs compared to the conventional newspaper, TV, and radio adverts that are expensive. 
These also make it possible and quicker to meet the standards set by the regulatory bodies 
regarding the threshold number of participants that validate clinical research. An example of 
technology at play in the planning phase is the CTTI’s Digital Trials (DHT) Program that was 
implemented in 2015 to identify and address challenges in planning for and conducting clinical 
trials. The program focuses on the use of digital health technologies for the collection of objective 
data (measured directly by the digital technology) in FDA-regulated clinical trials after participant 
consent (Geoghegan et. al., (2020).  The expansion of such programs will help fast-track planning 
processes and getting regulatory approval.   
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There is also a need for regulatory bodies such as the FDA to adopt electronic databases 
that allow researchers to submit required documents electronically instead of the traditional way 
which is paper based. One of the key issues that could be addressed that had traditionally limited 
the approval of regulatory bodies is patients’ privacy. Particularly, blockchain technologies have 
been identified as key to ensuring the privacy of patients and data protection. According to 
Benchoufi, Altman, and Ravaud (2019) blockchain is a secure and distributed data store or ledger 
ordered records of data that is incorruptible. It allows participants to receive copies of data and 
validate by consensus the transaction via a strong cryptographic process. The adoption of this 
technology in providing regulatory approvals will help ensure a fast turnaround for clinical trials 
to commence. An example of blockchain at work is the development of Embleema, which is a 
distributed electronic health record system that was developed to grant patients more control over 
their data and even organizes a data brokerage market place. Another example of clinical trials 
performed on a blockchain is TrialChain that was implemented over an original Blockchain 
architecture, where the state of private Blockchain is synchronized to the public Ethereum 
Blockchain. Such systems make access to required data easy and create the necessary trust needed 
to validate clinical trials.  A key milestone that occurred in the clinical research planning and 
authorization process was by Pfizer. The pharmaceutical company received clearance from the 
Food and Drug Administration (FDA) to conduct a clinical trial entirely online ( Andrews, 
Kostelecky, Spritz, and Franco, 2017). This has led to the development of multiple technologies 
that support direct-to-patient clinical trials, including electronic informed consent systems and 
remote data collection processes (Andrews, Kostelecky, Spritz, and Franco, 2017).  Thus, 
technology can help assure compliance and obedience as it can send a reminder to the patient 
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remotely to get them to do whatever assessment required by the study, which necessitates its 
integration in clinical research.  
4.2. The Recruitment Process 
This study revealed significant issues with the recruitment process. The conventional 
method entails placing adverts in newspapers, television, or radio. These platforms are expensive 
and reach a limited audience. Andrews, Kostelecky, Spritz, and Franco (2017) explain that 
researchers sometimes have to pay a physician up to $5000 to convince their patients to participate 
in a clinical trial. Furthermore, these processes make the recruitment process laborious because 
researchers have to manually analyze the feedback and select participants. Notification of 
participants is also done manually, which extends the time taken to recruit and conduct the actual 
study. The lack of tools to facilitate the recruitment of participants and collect data has also limited 
clinical trials' pace. In some instances, clinical trials have been canceled because of the failure to 
meet the participant threshold. LaMorte (2016) also revealed significant trust-related issues in 
recruiting African Americans for clinical trials because they mistrusted research activities. 
However technology will increase transparency and accountability that will help develop the trust 
needed to convince African Ameriancs to participate in clinical studies. With the outbreak of the 
COVID-19 pandemic, most clinical trials have been hampered because of the widespread 
lockdown and need for patients' isolation. According to Segelov et al. (2020), the Coronavirus has 
compounded participant recruitment and data collection challenges. While these challenges 
continue to affect the clinical research process, several studies have revealed that the issues could 
be solved by adopting technologies that limit close contact with participants.  
The review shows that telemedicine and eConsent were the majorly adopted technologies 
during COVID-19. Telemedicine was typically used for routine checkups to detect adverse side 
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effects, particularly in Phase I clinical trials (Diebolt et al., (2019). Telehealth was also utilized in 
measuring objective results by enabling remore data collection during clinical strudies. Teleheath 
allows patients to update their dietary habits, medications, and other key health paramaters that 
could be used by researchers to assess the participants’ health. eConsent was revealed to be easy 
to use and implement innovations. The noted advantages of eConsent included enabling 
communication with research participants through video descriptions and questions to evaluate 
understanding (Breton, L., S., et al., 2020). The COVID-19 pandemic outbreak revealed that many 
clinics without any remote software were not prepared for such instances (Breton, Lamberti, Dion, 
Getz, 2020). Many clinical studies not related to COVID-19 had to either be shut down or put on 
hold since the FDA was reorganizing its priority towards COVID-19 studies.  
Another key benefit of technology in the recruitment process is that it provides access to a 
large pool of possible participants at a relatively low cost. Researchers could leverage technologies 
such as mobile phones and social media platforms to create awareness about the research and 
recruit participants as per the regulations set by HIPAA. Andrews, Kostelecky, Spritz, and Franco 
(2017) explain that today, the sponsor of a clinical trial can contact potential participants based on 
their digital data and it is as easy as doing a Google search. There are online services such as 
TrialX, which is a free service that matches participants to relevant clinical trials based on their 
health information. It also uses Twitter to match potential research subjects to clinical trials that 
suit their needs. For example, a study conducted by Yuan and colleagues (2014) used Facebook to 
recruit participants in a study associated with HIV stigma. The study successfully recruited 1404 
adults primarily through Facebook. Moreover, several apps such as the National Library of 
Medicine Pharmaceutical Product Development’s Clinical Trials app are being developed by 
sponsors and academic institutions to help patients find relevant clinical trials. Thus, these tools 
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when integrated into clinical research will facilitate the recruitment process, which is very critical 
to the validation and success of clinical research activities.  
4.3. Engagement and Retention 
The review revealed that the failure to retain participants is a significant issue in clinical 
research. Traditional clinical research processes require that researchers engage participants to 
ensure they commit to the end of the study. However, several issues arise that result in participant 
turnover. For example, LaMorte (2016) revealed that African Americans may not be responsive in 
a clinical trial because of historical mistrust. As such, recruiting and retaining them in a study is 
often challenging. Rosa et. al., (2015) also explained that retention of participants of a clinical 
study, especially during long follow-up periods after the conclusion of an intervention is often 
challenging. Traditionally, the process took significant staff effort and resulted in less-than-ideal 
retention rates. Technologies such as mobile phones, email, social media, and websites have 
altered how researchers engage participants. These technologies have a wide reach and provide 
meaningful engagement that is necessary to ensure the retention of participants. Vanaken and 
Masand (2019) also explain the use of multimedia components to improve participant awareness. 
Technologies such as eConsent allow researchers to collect individual participant data and 
metadata that allows for tailored participant engagement   
4.4. Data Collection 
The way the Coronavirus spread has been a critical issue in the continuance of clinical 
research. Clinical research often involves interactions with hundreds of participants. Monitoring 
these participants, collecting data, and reporting adverse events in the wake of the COVID-19 
pandemic has been challenging. The study by Majumder et al. (2017) shows that technology could 
help solve these barriers. Notably, wearable technologies in the future will help researchers to track 
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the behaviors of the participants and collect vital data on their health. These tools will enable real-
time access to patients' data for research purposes—inbuilt sensors in phones. Clothing and 
domestic devices will also make it possible to collect data and report adverse events remotely, 
thereby making the clinical research process easy and cost-effective (Bhelkar et al., 2016). An 
example of technology at play in data collection is the use of the ecological monetary assessment 
(EMA). The data collection tool is designed to collect data in real-time and deliver interventions 
for study participants (Rosa, Campbell, Miele, Brunner, & Winstanley, 2015). Researchers can 
also use wearable devices to collect data. The devices are synced with smartphone apps to facilitate 
compiling and analyzing vast amounts of data that would have been impossible with the traditional 
data collection and analysis methods. Electronic health records (EHR) are another tool for data 
collection. The dissemination of results is a critical aspect of clinical trials. Traditionally, this was 
done by publishing the results in a peer-review journal or other print publications. Technology has 
changed how dissemination occurs. Researchers could post results on platforms like Twitter, 
Facebook, PubPeer, ResearchGate, and Academia.edu.  
Conclusion 
Overall, this study revealed the need to adopt technology in clinical research to advance it 
during the COVID-19 pandemic. Clinical research aims to better the researchers' and public 
members' knowledge of diagnostic methods, diseases, and new treatments or medical devices that 
can advance patient care. Prevention, diagnosis, prognosis, treatment, and curing disease can be 
improved using the data generated from clinical research. The data generated is utilized in bettering 
patient care through the production of products and designing processes. There is a need to place 
more emphasis on clinical trial studies on human subjects' that are done remotely with technology 
. Clinical trials are usually done on human subjects to uncover knowledge of new treatments and 
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behavioral interventions. The treatments usually conducted in human trials usually entail assessing 
new novel vaccines, nutritional choices, drugs, nutritional supplements, and medical devices. The 
COVID-19 brought a lot of new perspectives to the clinical research field. The pandemic 
challenged the clinical research field to have backup plans that ensure clinical trials are carried out 
effectively should a pandemic occur. The pandemic also brought a new need to incorporate 
technology in clinical trials to minimize costs and save time.  
Clinical research has encountered many advancements across the years, with technology 
being the primary factor that accelerates clinical research growth. Technology has enabled 
researchers to carry out clinical trials remotely, thus minimizing costs and saving time. The use of 
technology, especially in the recruitment process, ensures that there is inclusivity. Research 
participants' wearable devices have enabled researchers to have real-time and accurate data, 
promoting clinical research productivity. Despite the growth and milestones that clinical research 
has achieved, the future of clinical research is auspicious by adapting the new technology in 
healthcare. Future technologies like artificial intelligence, algorithms, and extended reality models 
will bring new perspectives to the clinical research field. Thus, there is a need for the health sector 
stakeholders to develop policies that will ensure the adoption of these technologies to facilitate 
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